242 related articles for article (PubMed ID: 33650210)
1. Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system.
Dörks M; Jobski K; Hoffmann F; Douros A
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):707-715. PubMed ID: 33650210
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
3. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
[TBL] [Abstract][Full Text] [Related]
4. Safety profile of chloroquine and hydroxychloroquine: a disproportionality analysis of the FDA Adverse Event Reporting System database.
Papazisis G; Siafis S; Cepatyte D; Giannis D; Stamoula E; Tzachanis D; Egberts T
Eur Rev Med Pharmacol Sci; 2021 Oct; 25(19):6003-6012. PubMed ID: 34661260
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
Sato K; Mano T; Iwata A; Toda T
Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
[TBL] [Abstract][Full Text] [Related]
6. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
7. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
8. Rising cases of drug-induced pulmonary fibrosis: Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database, 2000-2022.
McCall KL; Hennig KR; Abe ZT; Dattler DN; Hurd KL; Portnoy SL; Zagoria ZJ
Pharmacoepidemiol Drug Saf; 2024 May; 33(5):e5797. PubMed ID: 38680101
[TBL] [Abstract][Full Text] [Related]
9. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS).
Evoy KE; Covvey JR; Peckham AM; Ochs L; Hultgren KE
Res Social Adm Pharm; 2019 Aug; 15(8):953-958. PubMed ID: 31303196
[TBL] [Abstract][Full Text] [Related]
10. An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.
Luo M; Wu B; Li Y; Wu F
Int J Clin Pharm; 2022 Oct; 44(5):1179-1187. PubMed ID: 35857159
[TBL] [Abstract][Full Text] [Related]
11. Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
Beyzarov E; Chen Y; Julg R; Naim K; Shah J; Gregory WW; Ayoub A; Caubel P
Drug Saf; 2021 Jan; 44(1):95-105. PubMed ID: 33354753
[TBL] [Abstract][Full Text] [Related]
12. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
13. A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.
Diaby V; Almutairi RD; Chen Z; Moussa RK; Berthe A
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):159-168. PubMed ID: 33186061
[No Abstract] [Full Text] [Related]
14. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
15. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
[TBL] [Abstract][Full Text] [Related]
16. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
[TBL] [Abstract][Full Text] [Related]
17. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
Tang H; Zhou L; Li X; Kinlaw AC; Yang JY; Moon AM; Barnes EL; Wang T
Int J Clin Pharm; 2021 Aug; 43(4):1116-1122. PubMed ID: 34328585
[TBL] [Abstract][Full Text] [Related]
19. Analysis of drug-induced posterior reversible encephalopathy syndrome using the food and drug administration adverse drug events reporting system database.
Lei CL; Gui XL; Wang LY; Guo YJ; Li Y
Expert Opin Drug Saf; 2024 May; 23(5):607-616. PubMed ID: 38478961
[TBL] [Abstract][Full Text] [Related]
20. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
